Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus



Status:Completed
Conditions:Cervical Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/7/2018
Start Date:August 2012
End Date:February 11, 2017

Use our guide to learn which trials are right for you!

A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus

This phase II trial studies how well alisertib works in treating patients with leiomyosarcoma
of the uterus that has come back or persistent. Alisertib may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth.

PRIMARY OBJECTIVES:

I. To assess the clinical activity of MLN8237 (alisertib) in patients with recurrent or
persistent leiomyosarcoma of the uterus who have received one or two prior cytotoxic
therapies and the frequency of patients who survive progression-free for at least 6 months
after initiating therapy or have objective tumor response.

SECONDARY OBJECTIVES:

I. To determine the frequency and severity of adverse events as assessed by Common
Terminology Criteria for Adverse Events version 4 (CTCAE v4) among women with leiomyosarcoma
treated with MLN8237.

II. To determine the distribution of progression-free survival (PFS) and overall survival
(OS).

TERTIARY OBJECTIVES:

I. To determine the relationship of Aurora A Kinase expression, measured by
immunohistochemistry, with objective response, PFS at 6 months, survival, and
progression-free survival.

OUTLINE:

Patients receive alisertib orally (PO) twice daily (BID) on days 1-7. Courses repeat every 21
days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years and
then every 6 months for 3 years.

Inclusion Criteria:

- Patients must have incurable recurrent or persistent uterine leiomyosarcoma;
histologic confirmation of the original primary tumor is required

- Patients must have measurable disease; measurable disease is defined by Response
Evaluation Criteria in Solid Tumors (RECIST) (version 1.1); measurable disease is
defined as at least one lesion that can be accurately measured in at least one
dimension (longest diameter to be recorded); each lesion must be >= 10 mm when
measured by computed tomography (CT), magnetic resonance imaging (MRI), or caliper
measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes
must be >= 15 mm in short axis when measured by CT or MRI

- Patients must have at least one "target lesion" to be used to assess response on this
protocol as defined by RECIST version 1.1; tumors within a previously irradiated field
will be designated as "non-target" lesions unless progression is documented or a
biopsy is obtained to confirm persistence at least 90 days following completion of
radiation therapy

- Patients must not be eligible for a higher priority Gynecologic Oncology Group (GOG)
protocol, if one exists; in general, this would refer to any active GOG phase III
protocol for the same patient population (12/10/2012)

- Patients who have received one prior regimen must have a GOG performance status of 0,
1, or 2; patients who have received two prior regimens must have a GOG performance
status of 0 or 1

- Patients should be free of active infection requiring antibiotics (with the exception
of uncomplicated urinary tract infection [UTI])

- Any hormonal therapy directed at the malignant tumor must be discontinued at least one
week prior to registration

- Any other prior therapy directed at the malignant tumor, including chemotherapy and
immunologic agents, must be discontinued at least three weeks prior to registration
(12/10/2012)

- Any prior radiation therapy must be discontinued at least four weeks prior to
registration (12/10/2012)

- Patients must have had at least one prior chemotherapeutic regimen for management of
leiomyosarcoma

- Patients are allowed to receive, but are not required to receive, one additional
cytotoxic regimen for management of recurrent or persistent disease (12/10/2012)

- Patients must NOT have received any prior therapy directed at Aurora kinase for
management of recurrent or persistent disease; patients who were treated on GOG-0250
(gemcitabine + docetaxel plus bevacizumab vs placebo) are eligible; treatment on
GOG-0250 would count as ONE prior regimen

- Leukocytes >= 3,000/mcL

- Absolute neutrophil count >= 1,500/mcL

- Platelets >= 100,000/mcL

- Serum creatinine =< institutional upper limit of normal (ULN) OR creatinine clearance
>= 60 mL/min/1.73m^2 (calculated or measured)

- Bilirubin =< ULN

- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN

- Alkaline phosphatase =< 2.5 x ULN

- Patients must have signed an approved informed consent and authorization permitting
release of personal health information

- Patients of childbearing potential must have a negative serum pregnancy test prior to
the study entry and be practicing an effective form of contraception; pregnant women
are excluded from this study

- Patients must be able to take oral medication and to maintain a fast for 2 hours
before and 1 hour after MLN8237 administration

- Patient must not have taken agents that effect gastric pH within 4 days (any proton
pump inhibitor), or 1 day (any histamine-2 antagonist) of the planned start of
therapy; patients must be able to avoid all other types of antacids for 2 hours before
and 2 hours after each dose of MLN8237

Exclusion Criteria:

- Patients who have had prior therapy with MLN8237 or taken part in a study of an
investigational compound or device within 4 weeks of entering this study

- Patients who have had surgery (excluding biopsy), radiotherapy, or chemotherapy within
4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to the planned start of
protocol treatment or those who have not recovered from adverse events due to agents
administered more than 4 weeks earlier; patients who have had hormonal agents within 1
week of the planned start of protocol treatment

- Patients with other invasive malignancies, with the exception of non-melanoma skin
cancer, carcinoma in situ of the cervix, or ductal carcinoma in situ of the breast,
are excluded if there is any evidence of other malignancy being present within the
last three years

- Patients who have received prior radiotherapy to any portion of the abdominal cavity
or pelvis OTHER THAN for the treatment of uterine leiomyosarcoma within the last three
years are excluded; thus, patients with a history of prior pelvic radiation for
uterine leiomyosarcoma are eligible; prior radiation for localized cancer of the
breast, head and neck, or skin is permitted, provided that it was completed more than
three years prior to registration, and the patient remains free of recurrent or
metastatic disease

- Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER
THAN for the treatment of uterine leiomyosarcoma within the last three years are
excluded; patients may have received prior adjuvant chemotherapy for localized breast
cancer, provided that it was completed more than three years prior to registration,
and that the patient remains free of recurrent or metastatic disease

- Patients who are nursing because there is an unknown but potential risk for adverse
events in nursing infants from MLN8237

- Patients with a history of central nervous system metastases and/or carcinomatous
meningitis

- Patients with a history of allergic reactions attributed to compounds of similar
chemical or biologic composition to MLN8237, including but not limited to established
allergic reaction to benzodiazepines

- Patients who are known to be human immunodeficiency virus (HIV) positive

- Patients who have had prior allogeneic bone marrow or organ transplantation

- Patients with a known history of uncontrolled sleep apnea syndrome and other
conditions that could result in excessive daytime sleepiness, such as severe chronic
obstructive pulmonary disease; requirement for supplemental oxygen; or any conditions
that could result in excessive toxicity associated with the benzodiazepine-like
effects of MLN8237

- Patients who require constant administration of proton pump inhibitor, H2 antagonist,
or pancreatic enzymes; intermittent uses of antacids or H2 antagonists are allowed

- Patients who are unable to swallow oral medication or to maintain a fast as required
for 2 hours before and 1 hour after MLN8237 administration or any condition that would
modify small bowel absorption of oral medications, including malabsorption, or
resection of pancreas or upper bowel

- Patients who have had treatment with clinically significant enzyme inducers, such as
the enzyme-inducing antiepileptic drugs phenytoin, carbamazepine, oxcarbazepine,
primidone or phenobarbital, or rifampin, rifabutin, rifapentine, or St. John's wort
within 14 days prior to the first dose of MLN8237 and during the study

- Patients who have had a myocardial infarction within 6 months prior to enrollment or
have New York Heart Association (NYHA) class III (marked limitation of physical
activity, comfortable at rest, but less than ordinary activity causes fatigue,
palpitation, or dyspnea) or IV (unable to carry out any physical activity without
discomfort, symptoms of cardiac insufficiency at rest, if any physical activity is
undertaken, discomfort is increased) heart failure, uncontrolled angina, severe
uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
ischemia or active conduction system abnormalities; prior to study entry, any
electrocardiogram (ECG) abnormality at screening has to be documented by the
investigator as not medically relevant

- Patients must limit alcohol consumption to no more than 1 standard unit of alcohol (12
oz beer [350 mL], 1.5 oz [45 mL] of 80-proof alcohol, or one 6-oz [175 mL] glass of
wine) per day during the study and for 30 days from the last dose of MLN8237; patients
who are unable to comply with these restrictions are not eligible
We found this trial at
50
sites
1200 Old York Road
Abington, Pennsylvania 19001
(215) 481–2000
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
?
mi
from
Abington, PA
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
(810) 262-9000
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
?
mi
from
Flint, MI
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
1111 Duff Ave
Ames, Iowa 50010
(866) 972-5477
McFarland Clinic PC-William R Bliss Cancer Center The William R. Bliss Cancer Center at Mary...
?
mi
from
Ames, IA
Click here to add this to my saved trials
2000 E Greenville St
Anderson, South Carolina 29621
(864) 512-4640
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
?
mi
from
Anderson, SC
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Ann Arbor, Michigan 48106
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Boise, ID
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28204
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
1-773-702-6180
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
10900 Euclid Ave
Cleveland, Ohio 44106
216-368-2000
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
3535 Olentangy River Rd
Columbus, Ohio 43214
(614) 566-5000
Riverside Methodist Hospital Serving central Ohio since 1892, Riverside Methodist Hospital is consistently ranked one...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Dearborn, Michigan 48124
?
mi
from
Dearborn, MI
Click here to add this to my saved trials
1111 6th Ave
Des Moines, Iowa 50314
(515) 247-3121
Mercy Medical Center - Des Moines Mercy Medical Center
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
700 E University Ave
Des Moines, Iowa 50316
(515) 263-5612
Iowa Lutheran Hospital Iowa Lutheran Hospital has a long history of serving the Des Moines...
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
1200 Pleasant St
Des Moines, Iowa 50309
(515) 241-6212
Iowa Methodist Medical Center Iowa Methodist Medical Center was established in 1901 in a single...
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
22101 Moross Rd
Detroit, Michigan 48236
(313) 343-4000
Saint John Hospital and Medical Center Founded in 1952, St. John Hospital and Medical Center...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
1 Genesys Pkwy
Grand Blanc, Michigan 48439
(810) 606-5000
Genesys Regional Medical Center Genesys Health System, a member of Ascension Health, is a group...
?
mi
from
Grand Blanc, MI
Click here to add this to my saved trials
80 Seymour St
Hartford, Connecticut 6102
(860) 545-5000
The Hartford Hospital Hartford Hospital is the major teaching hospital affiliated with the University of...
?
mi
from
Hartford, CT
Click here to add this to my saved trials
?
mi
from
Hartford, CT
Click here to add this to my saved trials
?
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Honolulu, Hawaii 96813
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
Indianapolis, Indiana 46260
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
535 Barnhill Dr
Indianapolis, Indiana 46202
(888) 600-4822
Indiana University Melvin and Bren Simon Cancer Center At the IU Simon Cancer Center, more...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
205 NE Ave
Jackson, Michigan 49201
(517) 788-4800
Allegiance Health Allegiance Health is a community-owned and locally-governed health system in Jackson, Michigan. We...
?
mi
from
Jackson, MI
Click here to add this to my saved trials
1215 E Michigan Ave
Lansing, Michigan 48912
(517) 364-1000
Sparrow Hospital Sparrow has grown to become the region's largest health system, and its diverse...
?
mi
from
Lansing, MI
Click here to add this to my saved trials
Livonia, Michigan 48154
?
mi
from
Livonia, MI
Click here to add this to my saved trials
9485 Mentor Ave
Mentor, Ohio 44060
(440) 205-5755
Lake University Ireland Cancer Center Lake Health is a private, not-for-profit leader in community health...
?
mi
from
Mentor, OH
Click here to add this to my saved trials
100 Grand St
New Britain, Connecticut 06050
(860) 224-5011
The Hospital of Central Connecticut The Hospital of Central Connecticut is dedicated to fostering, sustaining...
?
mi
from
New Britain, CT
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
940 NE 13th St
Oklahoma City, Oklahoma 73190
(405) 271-6458
University of Oklahoma Health Sciences Center The OU Health Sciences Center is composed of seven...
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
8303 Dodge Street
Omaha, Nebraska 68114
(402) 354–4000
Nebraska Methodist Hospital Methodist Hospital is a general medical and surgical hospital in Omaha, NE....
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Orlando, Florida 32803
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Pontiac, Michigan 48341
?
mi
from
Pontiac, MI
Click here to add this to my saved trials
Port Huron, Michigan 48060
?
mi
from
Port Huron, MI
Click here to add this to my saved trials
Providence, Rhode Island 02905
?
mi
from
Providence, RI
Click here to add this to my saved trials
800 S Washington Ave
Saginaw, Michigan 48601
(989) 907-8000
Saint Mary's of Michigan At St. Mary's of Michigan, we continue to grow our outreach...
?
mi
from
Saginaw, MI
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Springfield, Missouri 65804
?
mi
from
Springfield, MO
Click here to add this to my saved trials
1235 E Cherokee St
Springfield, Missouri 65804
(417) 820-2000
Mercy Hospital Springfield We're continuing a tradition of healing more than 120 years old. Mercy...
?
mi
from
Springfield, MO
Click here to add this to my saved trials
3801 South National Avenue
Springfield, Missouri 65807
(417) 269-6000
CoxHealth South Hospital U.S. News & World Report has ranked CoxHealth one of Missouri's best...
?
mi
from
Springfield, MO
Click here to add this to my saved trials
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
300 South 6th Avenue
West Reading, Pennsylvania 19611
(610) 988-8000
Reading Hospital At Reading Health System, advancing your health and wellness is our mission. When...
?
mi
from
West Reading, PA
Click here to add this to my saved trials
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials